Objective: To study the relationship between blood stasis syndrome (BSS) and platelet activation and its influencing factors in type 2 diabetic mellitus (DM).Methods: Platelet CD 62p , CD 63 expressions w...Objective: To study the relationship between blood stasis syndrome (BSS) and platelet activation and its influencing factors in type 2 diabetic mellitus (DM).Methods: Platelet CD 62p , CD 63 expressions were determined in 30 type 2 DM patients with BSS, 27 type 2 DM patients without BSS and 20 normal controls by flow cytometry. Results: CD 62p , CD 63 levels were significantly higher in type 2 DM group with BSS than those in the type 2 DM group without BSS and in the normal controls. CD 62p was positively correlated with CD 63 , while positive correlation existed between HbA 1c, LDLC and CD 62p in DM patients with BSS. Conclusions: The increased level of platelet activation was the primary molecular basis of BSS in type 2 DM. It was important to perform the syndrome differentiation of BSS and treatment of activating blood flow to remove BSS in type 2 DM.展开更多
目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取2015年3月至2016年1月南阳市第一人民医院收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例,对照组采用常规抗心绞痛及降糖药物治疗...目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取2015年3月至2016年1月南阳市第一人民医院收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例,对照组采用常规抗心绞痛及降糖药物治疗,观察组在对照组的基础上加用益心舒胶囊治疗,2组患者均治疗8周。治疗后统计2组患者临床疗效;检测并比较治疗前后2组患者血糖、血脂水平及血小板活化指标水平的变化。结果:与对照组比较,治疗后观察组临床症状改善及心电图改善显效比例及有效率均显著升高,无效比例显著降低(P<0.05或P<0.01);与治疗前比较,治疗后2组患者FBG、2 h PBG、Hb A1c及TG、TC、LDL-C水平均明显降低,且观察组显著低于对照组(P<0.05或P<0.01),而2组患者HDL-C水平明显升高,且观察组显著高于对照组(P<0.01);治疗后对照组仅PAC-1及MAR较治疗前有明显降低(P<0.05),而观察组LAP、CD62P、PAC-1及MAR均较治疗前显著降低,且显著低于对照组(P<0.01)。结论:益心舒胶囊可显著改善2型糖尿病合并冠心病心绞痛患者的血糖、血脂水平,明显抑制血小板活化,提高临床疗效。展开更多
文摘Objective: To study the relationship between blood stasis syndrome (BSS) and platelet activation and its influencing factors in type 2 diabetic mellitus (DM).Methods: Platelet CD 62p , CD 63 expressions were determined in 30 type 2 DM patients with BSS, 27 type 2 DM patients without BSS and 20 normal controls by flow cytometry. Results: CD 62p , CD 63 levels were significantly higher in type 2 DM group with BSS than those in the type 2 DM group without BSS and in the normal controls. CD 62p was positively correlated with CD 63 , while positive correlation existed between HbA 1c, LDLC and CD 62p in DM patients with BSS. Conclusions: The increased level of platelet activation was the primary molecular basis of BSS in type 2 DM. It was important to perform the syndrome differentiation of BSS and treatment of activating blood flow to remove BSS in type 2 DM.
文摘目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取2015年3月至2016年1月南阳市第一人民医院收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例,对照组采用常规抗心绞痛及降糖药物治疗,观察组在对照组的基础上加用益心舒胶囊治疗,2组患者均治疗8周。治疗后统计2组患者临床疗效;检测并比较治疗前后2组患者血糖、血脂水平及血小板活化指标水平的变化。结果:与对照组比较,治疗后观察组临床症状改善及心电图改善显效比例及有效率均显著升高,无效比例显著降低(P<0.05或P<0.01);与治疗前比较,治疗后2组患者FBG、2 h PBG、Hb A1c及TG、TC、LDL-C水平均明显降低,且观察组显著低于对照组(P<0.05或P<0.01),而2组患者HDL-C水平明显升高,且观察组显著高于对照组(P<0.01);治疗后对照组仅PAC-1及MAR较治疗前有明显降低(P<0.05),而观察组LAP、CD62P、PAC-1及MAR均较治疗前显著降低,且显著低于对照组(P<0.01)。结论:益心舒胶囊可显著改善2型糖尿病合并冠心病心绞痛患者的血糖、血脂水平,明显抑制血小板活化,提高临床疗效。
